[144] BeOne Medicines Ltd. SEC Filing

Rhea-AI Filing Summary

BeOne Medicines Ltd. (BEIGF) insider filing shows a proposed sale of 27,803 ADS through Morgan Stanley Smith Barney, with an aggregate market value of $9,238,102.81 and approximately 54,564,278 ADS outstanding. The securities were acquired as Restricted Stock Units on 04/30/2022. The filer reported multiple Rule 10b5-1 sales in the past three months: 27,802 ADS on 07/09/2025 for $7,044,590.31; 1,661 ADS on 07/08/2025 for $406,520.95; 3,174 ADS on 06/23/2025 for $830,359.98; and 1,460 ADS on 06/17/2025 for $374,473.21, totaling 34,097 ADS sold for $8,655,944.45. The notice states the seller represents no undisclosed material adverse information and references reliance on Rule 10b5-1 where applicable.

Positive

• None.

Negative

• Proposed sale of 27,803 ADS valued at $9,238,102.81 which represents insider liquidity
• Recent sales of 34,097 ADS in past three months totaling $8,655,944.45 under Rule 10b5-1, indicating substantial recent disposals

Insights

Securities Analyst

TL;DR: Insider proposes a multi-million-dollar ADS sale; recent 10b5-1 activity shows significant disposals in past three months.

The filing documents a proposed Rule 144 sale of 27,803 ADS valued at $9.24 million and confirms these ADS were issued as restricted stock units on 04/30/2022. Recent executed 10b5-1 transactions total 34,097 ADS for $8.66 million over June–July 2025. For investors, this represents meaningful insider liquidity but is a disclosed, rule-compliant process. The filing provides transaction dates, amounts, and gross proceeds but does not include any commentary on intent or company operational details.

Corporate Governance Expert

TL;DR: The disclosure follows Rule 144 and references Rule 10b5-1 plans, indicating formal, prearranged sales rather than ad hoc trades.

The notice affirms the signer does not possess undisclosed material adverse information and lists dates of prior 10b5-1 sales and plan-related details. This transparency aligns with governance best practices for executive/insider disposals. However, the document lacks the filer CIK/identifying contact details in the provided excerpt and does not state the date of any 10b5-1 plan adoption within the visible fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	27803	9238102.81	54564278	09/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	04/30/2022	Restricted Stock Units	Issuer			27803	04/30/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JOHN OYLER Aeschengraben 27, 21st Floor Basel V8 4051	ADS	07/09/2025	27802	7044590.31
10b5-1 Sales for PAN-OYLER FOUNDATION Aeschengraben 27, 21st Floor Basel V8 4051	ADS	07/08/2025	1661	406520.95
10b5-1 Sales for JOHN OYLER Aeschengraben 27, 21st Floor Basel V8 4051	ADS	06/23/2025	3174	830359.98
10b5-1 Sales for JOHN OYLER Aeschengraben 27, 21st Floor Basel V8 4051	ADS	06/17/2025	1460	374473.21

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What ADS sale is proposed in the BeOne Medicines (BEIGF) Form 144?

The filing proposes sale of 27,803 ADS through Morgan Stanley Smith Barney with an aggregate market value of $9,238,102.81 and approximately 54,564,278 ADS outstanding.

When were the securities to be sold acquired?

The ADS were acquired as Restricted Stock Units on 04/30/2022 and the amount to be sold is listed as 27,803 ADS.

What 10b5-1 sales by the filer occurred in the past three months?

Reported 10b5-1 sales: 27,802 ADS on 07/09/2025 for $7,044,590.31; 1,661 ADS on 07/08/2025 for $406,520.95; 3,174 ADS on 06/23/2025 for $830,359.98; and 1,460 ADS on 06/17/2025 for $374,473.21.

Does the filing state reliance on a 10b5-1 trading plan?

The notice references Rule 10b5-1 sales and includes a representation that the signer does not know of undisclosed material adverse information; the form includes fields for plan adoption date but no adoption date is visible in the provided excerpt.

Who is the broker handling the proposed sale?

The broker listed for the proposed sale is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York NY 10004.